Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Acquires 200,000 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 200,000 shares of OPKO Health stock in a transaction on Monday, March 17th. The stock was purchased at an average cost of $1.74 per share, with a total value of $348,000.00. Following the completion of the transaction, the chief executive officer now directly owns 213,501,448 shares in the company, valued at $371,492,519.52. This represents a 0.09 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, February 28th, Phillip Md Et Al Frost acquired 67,434 shares of OPKO Health stock. The stock was purchased at an average cost of $1.71 per share, with a total value of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost bought 47,537 shares of OPKO Health stock. The shares were bought at an average cost of $1.47 per share, with a total value of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock. The shares were bought at an average cost of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.48 per share, for a total transaction of $740,000.00.

OPKO Health Price Performance

Shares of OPKO Health stock opened at $1.81 on Tuesday. The firm has a market cap of $1.22 billion, a PE ratio of -9.53 and a beta of 1.70. OPKO Health, Inc. has a 12-month low of $0.86 and a 12-month high of $2.04. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The company’s fifty day simple moving average is $1.63 and its two-hundred day simple moving average is $1.57.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The business had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. As a group, equities analysts expect that OPKO Health, Inc. will post -0.25 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on OPK. Barrington Research restated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research note on Wednesday, March 12th. StockNews.com upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd. Finally, HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, March 12th.

Institutional Investors Weigh In On OPKO Health

Large investors have recently modified their holdings of the stock. FMR LLC lifted its position in OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 11,089 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in OPKO Health by 75.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock worth $42,000 after buying an additional 12,417 shares during the last quarter. Orion Portfolio Solutions LLC bought a new position in OPKO Health during the third quarter valued at approximately $45,000. Cibc World Markets Corp bought a new position in OPKO Health during the fourth quarter valued at approximately $45,000. Finally, Zacks Investment Management bought a new position in OPKO Health during the fourth quarter valued at approximately $49,000. Institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.